Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection

Söderholm, Jonas; Waldenström, Jesper; Askarieh, Galia; Pilli, Massimo; Bochud, Pierre-Yves; Negro, Francesco; Pawlotsky, Jean-Michel; Zeuzem, Stefan; Ferrari, Carlo; Norkrans, Gunnar; Wejstål, Rune; Westin, Johan; Neumann, Avidan U; Haagmans, Bart L; Lindh, Magnus; Missale, Gabriele; Hellstrand, Kristoffer; Lagging, Martin

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection
Authors		Söderholm, Jonas Waldenström, Jesper Askarieh, Galia Pilli, Massimo Bochud, Pierre-Yves Negro, Francesco Pawlotsky, Jean-Michel Zeuzem, Stefan Ferrari, Carlo Norkrans, Gunnar Wejstål, Rune Westin, Johan Neumann, Avidan U Haagmans, Bart L Lindh, Magnus Missale, Gabriele Hellstrand, Kristoffer Lagging, Martin show all authors [1 - 18]
Published in		PLOS ONE. 2013, vol. 8, no. 2, p. e56991
Abstract		Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.
Identifiers		DOI: 10.1371/journal.pone.0056991 PMID: 23437290
Full text		Article (Published version) (363 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie
Research group		Etudes et traitement de l'hépatite C et B (554)
Citation (ISO format)		SÖDERHOLM, Jonas et al. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. In: PLOS ONE, 2013, vol. 8, n° 2, p. e56991. https://archive-ouverte.unige.ch/unige:27155